The Application Notebook
Synthetic cannabis products have garnered a great deal of media attention recently. Countless products are being sold at smoke shops, convenience stores, and online sites.
Synthetic cannabis products have garnered a great deal of media attention recently. Countless products are being sold at smoke shops, convenience stores, and online sites. These products are labeled "not for human consumption," but have been reported to have effects similar to cannabis when smoked. These reports have prompted testing in crime laboratories across the country. Some of the products tested have been confirmed to contain synthetic cannabinoids. The identification of these compounds by GC–MS can be challenging, as most of them are not present in commercially available mass spectral libraries. A particular product that received a great deal of media attention in the midwestern United States during 2010 was "Mr. Smiley." This product was reported to contain natural substances such as Mullein and Damiana leaf. It was also reported that when smoked, this product exhibited a "THC-like" high. Shortly before this product was pulled from store shelves, some was purchased for analysis to determine which compounds may be present.
Figure 1: GCâHRT TIC and extracted ion chromatogram for the analyte identified as 1-pentyl-3-(1-naphthoyl)indole or JWH-018. Notice a mass accuracy of 0.2 ppm was achieved.
The sample was initially analyzed by GC–TOFMS, but the most abundant analyte detected was not present in the commercially available NIST mass spectral database.
This application note shows the use of LECO's Pegasus GC–HRT high resolution time-of-flight mass spectrometer to provide an elemental composition based on accurate mass data, which ultimately lead to identification of the unknown compound.
A 1-gram sample of "Mr. Smiley" was weighed into a 20-mL vial. A 10-mL aliquot of ethyl acetate was added and the sample was sonicated for 10 min.
The "Mr. Smiley" extract was analyzed on a LECO Pegasus GC–HRT system using the conditions shown below.
GC: Agilent 7890
Injection: 1 μL, split 50:1 at 275 °C
Column: Rtx-5, 10 m x 0.18 mm x 0.2 μm
Carrier gas: helium at 1.0 mL/min
Oven: 60 °C to 330 °C @ 50 °C/min, hold 10 min
Transfer Line: 300 °C
MS: LECO Pegasus GC–HRT
Acquisition Delay: 120 s
Saved mass range: 40–550 m/z
Flight Path: High Resolution (R = 25,000 FWHM)
Acquisition rate: 20 spectra/s
Source temperature: 250 °C
The accurate mass data provided by the Pegasus GC-HRT was consistent with the formula C24H23NO. A literature search lead to identification of this formula as 1-pentyl-3-(1-naphthoyl)indole, or JWH-018, one of the most common synthetic cannabinoids used in "herbal incense" products.
This application shows how the high resolving power and mass accuracy of the Pegasus GC–HRT facilitate identification of substances absent from commercially available mass spectral libraries. This ability will be required as new abused substances are continually developed.
LECO Corporation
3000 Lakeview Avenue, St. Joseph, MI 49085
tel. (269) 985-5496, fax (269) 982-8977
Website: www.leco.com
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.